Frazier Life Sciences Management, L.P.
An institutional investment manager in PALO ALTO, CA. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 14, 2026. SEC CIK 1892134.
- Reported value$4.59bn
- Positions41
Holdings: 41 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Mirum Pharmaceuticals IncMIRM | COM | 604749101 | 899 | 19.6% | 7,679,684 | Unchanged | |
| Newamsterdam Pharma Company | ORDINARY SHARES | N62509109 | 613 | 13.3% | 18,088,902 | Added+1,145,128 | |
| Erasca IncERAS | COM | 29479A108 | 458 | 10.0% | 24,975,188 | Added+300,000 | |
| MBX Biosciences IncMBX | COM | 55287L101 | 367 | 8.0% | 6,652,013 | Unchanged | |
| Arcutis Biotherapeutics IncARQT | COM | 03969K108 | 259 | 5.6% | 9,874,511 | Unchanged | |
| Trevi Therapeutics IncTRVI | COM | 89532M101 | 185 | 4.0% | 9,939,447 | Reduced−100 | |
| Krystal Biotech IncKRYS | COM | 501147102 | 179 | 3.9% | 481,307 | Unchanged | |
| Maze Therapeutics IncMAZE | COM | 578784100 | 150 | 3.3% | 5,032,915 | Added+465,641 | |
| Phathom Pharmaceuticals IncPHAT | COM | 71722W107 | 135 | 2.9% | 12,466,489 | Unchanged | |
| Palvella Therapeutics Inc NePVLA | COM | 697947109 | 135 | 2.9% | 882,400 | Unchanged | |
| Bridgebio Pharma IncBBIO | COM | 10806X102 | 115 | 2.5% | 1,548,139 | Reduced−1,900,000 | |
| Disc Medicine IncIRON | COM | 254604101 | 99.1 | 2.2% | 1,354,852 | Unchanged | |
| Cytokinetics IncCYTK | COM NEW | 23282W605 | 98.8 | 2.2% | 1,159,879 | Unchanged | |
| Dyne Therapeutics IncDYN | COM | 26818M108 | 70.0 | 1.5% | 3,153,082 | Unchanged | |
| Ascendis Pharma A/S | SPONSORED ADR | 04351P101 | 60.1 | 1.3% | 225,155 | Added+91,822 | |
| Savara IncSVRA | COM | 805111101 | 59.9 | 1.3% | 9,720,852 | Unchanged | |
| Parabilis Medicines IncPBLS | COM | 698955101 | 52.6 | 1.1% | 1,920,805 | New+1,920,805 | |
| Aura Biosciences IncAURA | COM | 05153U107 | 50.4 | 1.1% | 7,100,000 | Added+2,000,000 | |
| Achieve Life Science IncACHV | COM | 004468500 | 49.7 | 1.1% | 7,614,836 | New+7,614,836 | |
| VOR Biopharma IncVOR | COM NEW | 929033207 | 46.8 | 1.0% | 2,543,939 | Unchanged | |
| Allogene Therapeutics IncALLO | COM | 019770106 | 46.7 | 1.0% | 22,446,668 | Added+18,650,000 | |
| Tarsus Pharmaceuticals IncTARS | COM | 87650L103 | 45.9 | 1.0% | 728,644 | Unchanged | |
| Biocryst Pharmaceuticals IncBCRX | COM | 09058V103 | 40.1 | 0.9% | 4,009,240 | Unchanged | |
| Alkermes plc | SHS | G01767105 | 36.7 | 0.8% | 700,647 | Unchanged | |
| Acadia Pharmaceuticals IncACAD | COM | 004225108 | 36.4 | 0.8% | 1,438,198 | Unchanged | |
| ZAI Lab LtdZLAB | ADR | 98887Q104 | 36.1 | 0.8% | 1,902,320 | Unchanged | |
| Mannkind CorpMNKD | COM NEW | 56400P706 | 28.1 | 0.6% | 6,600,000 | Added+700,000 | |
| Design Therapeutics IncDSGN | COM | 25056L103 | 26.2 | 0.6% | 1,809,854 | New+1,809,854 | |
| Aclaris Therapeutics IncACRS | COM | 00461U105 | 26.1 | 0.6% | 4,925,374 | Unchanged | |
| Shattuck Labs IncSTTK | COM | 82024L103 | 26.0 | 0.6% | 3,750,000 | New+3,750,000 | |
| Kailera Therapeutics IncKLRA | COMMON STOCK | 482931102 | 24.2 | 0.5% | 1,100,000 | New+1,100,000 | |
| Monte Rosa Therapeutics IncGLUE | COM | 61225M102 | 24.2 | 0.5% | 1,000,000 | Unchanged | |
| Lexeo Therapeutics IncLXEO | COM | 52886X107 | 22.5 | 0.5% | 4,824,725 | Added+400,000 | |
| Relay Therapeutics IncRLAY | COM | 75943R102 | 19.0 | 0.4% | 1,015,693 | New+1,015,693 | |
| Evolus IncEOLS | COM | 30052C107 | 18.3 | 0.4% | 2,630,665 | Unchanged | |
| Immunocore Holdings plcIMCR | ADS | 45258D105 | 15.4 | 0.3% | 484,782 | Unchanged | |
| Valneva SEVALN | SPONSORED ADS | 92025Y103 | 12.0 | 0.3% | 2,291,666 | Unchanged | |
| Newamsterdam Pharma Company | *W EXP 99/99/999 | N62509117 | 10.7 | 0.2% | 500,333 | Unchanged | |
| Autolus Therapeutics LtdAUTL | SPON ADS | 05280R100 | 7.1 | 0.2% | 4,447,910 | Unchanged | |
| Xilio Therapeutics IncXLO | COM | 98422T209 | 4.0 | <0.1% | 422,505 | Unchanged | |
| Ibio IncIBIO | COM NEW | 451033708 | 3.4 | <0.1% | 1,953,467 | Unchanged |
Sold out: 3 positions
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Agios Pharmaceuticals IncAGIO | COM | 00847X104 | 0.0 | 0.0% | 0 | Sold out−1,256,080 | |
| Kalvista Pharmaceuticals Inc | COM | 483497103 | 0.0 | 0.0% | 0 | Sold out−4,961,108 | |
| Revolution Medicines IncRVMD | COM | 76155X100 | 0.0 | 0.0% | 0 | Sold out−675,686 |
Source: SEC EDGAR, Form 13F-HR, accession 0001892134-26-000003 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.